nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—SLCO1B1—Methotrexate—lymphatic system cancer	0.105	1	CbGbCtD
Penicillamine—Alveolitis allergic—Fludarabine—lymphatic system cancer	0.0302	0.0338	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Fludarabine—lymphatic system cancer	0.0179	0.02	CcSEcCtD
Penicillamine—Leukaemia—Vincristine—lymphatic system cancer	0.0179	0.02	CcSEcCtD
Penicillamine—Guillain-Barre syndrome—Methotrexate—lymphatic system cancer	0.0161	0.018	CcSEcCtD
Penicillamine—Bone marrow depression—Teniposide—lymphatic system cancer	0.0133	0.0149	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Bleomycin—lymphatic system cancer	0.0132	0.0147	CcSEcCtD
Penicillamine—Optic neuritis—Fludarabine—lymphatic system cancer	0.0128	0.0143	CcSEcCtD
Penicillamine—Trauma—Bleomycin—lymphatic system cancer	0.0122	0.0136	CcSEcCtD
Penicillamine—Bone marrow depression—Fludarabine—lymphatic system cancer	0.0117	0.0131	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Carmustine—lymphatic system cancer	0.0115	0.0128	CcSEcCtD
Penicillamine—Extravasation—Teniposide—lymphatic system cancer	0.0103	0.0115	CcSEcCtD
Penicillamine—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.0102	0.0114	CcSEcCtD
Penicillamine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00979	0.0109	CcSEcCtD
Penicillamine—Epigastric pain—Mitoxantrone—lymphatic system cancer	0.00972	0.0108	CcSEcCtD
Penicillamine—Interstitial pneumonia—Mitoxantrone—lymphatic system cancer	0.00972	0.0108	CcSEcCtD
Penicillamine—Proteinuria—Fludarabine—lymphatic system cancer	0.00898	0.01	CcSEcCtD
Penicillamine—Alveolitis allergic—Methotrexate—lymphatic system cancer	0.00896	0.01	CcSEcCtD
Penicillamine—Protein urine present—Fludarabine—lymphatic system cancer	0.00886	0.00989	CcSEcCtD
Penicillamine—Leukaemia—Methotrexate—lymphatic system cancer	0.00869	0.0097	CcSEcCtD
Penicillamine—Neuropathy—Teniposide—lymphatic system cancer	0.00843	0.00941	CcSEcCtD
Penicillamine—Interstitial lung disease—Bleomycin—lymphatic system cancer	0.00817	0.00913	CcSEcCtD
Penicillamine—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.00746	0.00833	CcSEcCtD
Penicillamine—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.00726	0.0081	CcSEcCtD
Penicillamine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00722	0.00806	CcSEcCtD
Penicillamine—Bone marrow depression—Vincristine—lymphatic system cancer	0.00714	0.00798	CcSEcCtD
Penicillamine—Interstitial lung disease—Carmustine—lymphatic system cancer	0.00714	0.00797	CcSEcCtD
Penicillamine—Bone marrow depression—Mitoxantrone—lymphatic system cancer	0.00696	0.00777	CcSEcCtD
Penicillamine—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.00663	0.00741	CcSEcCtD
Penicillamine—Extravasation—Bleomycin—lymphatic system cancer	0.00663	0.00741	CcSEcCtD
Penicillamine—Hepatic failure—Fludarabine—lymphatic system cancer	0.00637	0.00712	CcSEcCtD
Penicillamine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00636	0.0071	CcSEcCtD
Penicillamine—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00615	0.00686	CcSEcCtD
Penicillamine—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00612	0.00683	CcSEcCtD
Penicillamine—Extravasation—Carmustine—lymphatic system cancer	0.00579	0.00646	CcSEcCtD
Penicillamine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0057	0.00637	CcSEcCtD
Penicillamine—Extravasation—Vincristine—lymphatic system cancer	0.00553	0.00617	CcSEcCtD
Penicillamine—Alopecia—Mechlorethamine—lymphatic system cancer	0.0054	0.00604	CcSEcCtD
Penicillamine—Extravasation—Mitoxantrone—lymphatic system cancer	0.00538	0.00601	CcSEcCtD
Penicillamine—Leukocytosis—Carmustine—lymphatic system cancer	0.00537	0.006	CcSEcCtD
Penicillamine—Pancytopenia—Teniposide—lymphatic system cancer	0.00535	0.00597	CcSEcCtD
Penicillamine—Proteinuria—Mitoxantrone—lymphatic system cancer	0.00534	0.00597	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Methotrexate—lymphatic system cancer	0.00532	0.00594	CcSEcCtD
Penicillamine—Protein urine present—Mitoxantrone—lymphatic system cancer	0.00527	0.00589	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00516	0.00576	CcSEcCtD
Penicillamine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00492	0.0055	CcSEcCtD
Penicillamine—Stomatitis—Teniposide—lymphatic system cancer	0.0049	0.00547	CcSEcCtD
Penicillamine—Interstitial pneumonia—Methotrexate—lymphatic system cancer	0.00484	0.00541	CcSEcCtD
Penicillamine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00477	0.00532	CcSEcCtD
Penicillamine—Neuropathy—Carmustine—lymphatic system cancer	0.00474	0.0053	CcSEcCtD
Penicillamine—Pancytopenia—Fludarabine—lymphatic system cancer	0.0047	0.00525	CcSEcCtD
Penicillamine—Appetite absent—Methotrexate—lymphatic system cancer	0.0047	0.00525	CcSEcCtD
Penicillamine—Injury—Bleomycin—lymphatic system cancer	0.00457	0.0051	CcSEcCtD
Penicillamine—Haemoglobin—Teniposide—lymphatic system cancer	0.00453	0.00506	CcSEcCtD
Penicillamine—Neuropathy—Vincristine—lymphatic system cancer	0.00453	0.00506	CcSEcCtD
Penicillamine—Haemorrhage—Teniposide—lymphatic system cancer	0.00451	0.00504	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0045	0.00503	CcSEcCtD
Penicillamine—Mouth ulceration—Vincristine—lymphatic system cancer	0.00436	0.00487	CcSEcCtD
Penicillamine—Renal failure—Fludarabine—lymphatic system cancer	0.00434	0.00485	CcSEcCtD
Penicillamine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00433	0.00483	CcSEcCtD
Penicillamine—Stomatitis—Fludarabine—lymphatic system cancer	0.0043	0.00481	CcSEcCtD
Penicillamine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00425	0.00475	CcSEcCtD
Penicillamine—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00424	0.00473	CcSEcCtD
Penicillamine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00422	0.00471	CcSEcCtD
Penicillamine—Haematuria—Fludarabine—lymphatic system cancer	0.00421	0.0047	CcSEcCtD
Penicillamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00414	0.00463	CcSEcCtD
Penicillamine—Injury—Carmustine—lymphatic system cancer	0.00399	0.00445	CcSEcCtD
Penicillamine—Alopecia—Teniposide—lymphatic system cancer	0.00398	0.00445	CcSEcCtD
Penicillamine—Haemoglobin—Fludarabine—lymphatic system cancer	0.00398	0.00445	CcSEcCtD
Penicillamine—Haemorrhage—Fludarabine—lymphatic system cancer	0.00396	0.00443	CcSEcCtD
Penicillamine—Hepatic failure—Vincristine—lymphatic system cancer	0.00389	0.00435	CcSEcCtD
Penicillamine—Eruption—Methotrexate—lymphatic system cancer	0.0038	0.00425	CcSEcCtD
Penicillamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00378	0.00422	CcSEcCtD
Penicillamine—Anaemia—Teniposide—lymphatic system cancer	0.00363	0.00405	CcSEcCtD
Penicillamine—Agitation—Teniposide—lymphatic system cancer	0.00361	0.00403	CcSEcCtD
Penicillamine—Leukopenia—Teniposide—lymphatic system cancer	0.00351	0.00392	CcSEcCtD
Penicillamine—Alopecia—Fludarabine—lymphatic system cancer	0.0035	0.00391	CcSEcCtD
Penicillamine—Bone marrow depression—Methotrexate—lymphatic system cancer	0.00347	0.00387	CcSEcCtD
Penicillamine—Pancytopenia—Bleomycin—lymphatic system cancer	0.00345	0.00385	CcSEcCtD
Penicillamine—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00331	0.00369	CcSEcCtD
Penicillamine—Muscular weakness—Carmustine—lymphatic system cancer	0.00323	0.00361	CcSEcCtD
Penicillamine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0032	0.00358	CcSEcCtD
Penicillamine—Anaemia—Fludarabine—lymphatic system cancer	0.00319	0.00356	CcSEcCtD
Penicillamine—Agitation—Fludarabine—lymphatic system cancer	0.00317	0.00354	CcSEcCtD
Penicillamine—Stomatitis—Bleomycin—lymphatic system cancer	0.00316	0.00352	CcSEcCtD
Penicillamine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00314	0.0035	CcSEcCtD
Penicillamine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00311	0.00348	CcSEcCtD
Penicillamine—Leukopenia—Fludarabine—lymphatic system cancer	0.00309	0.00345	CcSEcCtD
Penicillamine—Muscular weakness—Vincristine—lymphatic system cancer	0.00309	0.00345	CcSEcCtD
Penicillamine—Haematuria—Bleomycin—lymphatic system cancer	0.00309	0.00345	CcSEcCtD
Penicillamine—Anorexia—Teniposide—lymphatic system cancer	0.00305	0.00341	CcSEcCtD
Penicillamine—Pancytopenia—Carmustine—lymphatic system cancer	0.00301	0.00336	CcSEcCtD
Penicillamine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00297	0.00332	CcSEcCtD
Penicillamine—Arthralgia—Fludarabine—lymphatic system cancer	0.00294	0.00328	CcSEcCtD
Penicillamine—Haemoglobin—Bleomycin—lymphatic system cancer	0.00292	0.00326	CcSEcCtD
Penicillamine—Haemorrhage—Bleomycin—lymphatic system cancer	0.00291	0.00324	CcSEcCtD
Penicillamine—Pancytopenia—Vincristine—lymphatic system cancer	0.00287	0.00321	CcSEcCtD
Penicillamine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.0028	0.00312	CcSEcCtD
Penicillamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00278	0.00311	CcSEcCtD
Penicillamine—Renal failure—Carmustine—lymphatic system cancer	0.00278	0.0031	CcSEcCtD
Penicillamine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00277	0.00309	CcSEcCtD
Penicillamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00276	0.00309	CcSEcCtD
Penicillamine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00276	0.00308	CcSEcCtD
Penicillamine—Stomatitis—Carmustine—lymphatic system cancer	0.00275	0.00308	CcSEcCtD
Penicillamine—Rash—Mechlorethamine—lymphatic system cancer	0.00274	0.00306	CcSEcCtD
Penicillamine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00274	0.00306	CcSEcCtD
Penicillamine—Anorexia—Fludarabine—lymphatic system cancer	0.00268	0.003	CcSEcCtD
Penicillamine—Extravasation—Methotrexate—lymphatic system cancer	0.00268	0.00299	CcSEcCtD
Penicillamine—Proteinuria—Methotrexate—lymphatic system cancer	0.00266	0.00297	CcSEcCtD
Penicillamine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00264	0.00295	CcSEcCtD
Penicillamine—Stomatitis—Vincristine—lymphatic system cancer	0.00263	0.00294	CcSEcCtD
Penicillamine—Protein urine present—Methotrexate—lymphatic system cancer	0.00263	0.00293	CcSEcCtD
Penicillamine—Renal failure—Mitoxantrone—lymphatic system cancer	0.00258	0.00288	CcSEcCtD
Penicillamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00258	0.00288	CcSEcCtD
Penicillamine—Alopecia—Bleomycin—lymphatic system cancer	0.00257	0.00287	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00257	0.00286	CcSEcCtD
Penicillamine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00256	0.00286	CcSEcCtD
Penicillamine—Haemoglobin—Carmustine—lymphatic system cancer	0.00255	0.00285	CcSEcCtD
Penicillamine—Urticaria—Teniposide—lymphatic system cancer	0.00255	0.00284	CcSEcCtD
Penicillamine—Glossitis—Methotrexate—lymphatic system cancer	0.00254	0.00283	CcSEcCtD
Penicillamine—Haemorrhage—Carmustine—lymphatic system cancer	0.00254	0.00283	CcSEcCtD
Penicillamine—Body temperature increased—Teniposide—lymphatic system cancer	0.00253	0.00283	CcSEcCtD
Penicillamine—Haematuria—Mitoxantrone—lymphatic system cancer	0.0025	0.0028	CcSEcCtD
Penicillamine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00245	0.00274	CcSEcCtD
Penicillamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00245	0.00273	CcSEcCtD
Penicillamine—Vasculitis—Methotrexate—lymphatic system cancer	0.0024	0.00268	CcSEcCtD
Penicillamine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00239	0.00267	CcSEcCtD
Penicillamine—Urethral disorder—Vincristine—lymphatic system cancer	0.00237	0.00265	CcSEcCtD
Penicillamine—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00237	0.00265	CcSEcCtD
Penicillamine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00236	0.00264	CcSEcCtD
Penicillamine—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00236	0.00263	CcSEcCtD
Penicillamine—Anaemia—Bleomycin—lymphatic system cancer	0.00234	0.00261	CcSEcCtD
Penicillamine—Leukopenia—Bleomycin—lymphatic system cancer	0.00226	0.00253	CcSEcCtD
Penicillamine—Alopecia—Carmustine—lymphatic system cancer	0.00224	0.0025	CcSEcCtD
Penicillamine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00223	0.00249	CcSEcCtD
Penicillamine—Mental disorder—Carmustine—lymphatic system cancer	0.00222	0.00248	CcSEcCtD
Penicillamine—Angiopathy—Vincristine—lymphatic system cancer	0.0022	0.00245	CcSEcCtD
Penicillamine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.0022	0.00245	CcSEcCtD
Penicillamine—Diarrhoea—Teniposide—lymphatic system cancer	0.00219	0.00245	CcSEcCtD
Penicillamine—Alopecia—Vincristine—lymphatic system cancer	0.00214	0.00239	CcSEcCtD
Penicillamine—Mental disorder—Vincristine—lymphatic system cancer	0.00212	0.00237	CcSEcCtD
Penicillamine—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00212	0.00236	CcSEcCtD
Penicillamine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00208	0.00233	CcSEcCtD
Penicillamine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00207	0.00232	CcSEcCtD
Penicillamine—Anaemia—Carmustine—lymphatic system cancer	0.00204	0.00228	CcSEcCtD
Penicillamine—Vomiting—Teniposide—lymphatic system cancer	0.00204	0.00227	CcSEcCtD
Penicillamine—Agitation—Carmustine—lymphatic system cancer	0.00203	0.00227	CcSEcCtD
Penicillamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00202	0.00226	CcSEcCtD
Penicillamine—Rash—Teniposide—lymphatic system cancer	0.00202	0.00226	CcSEcCtD
Penicillamine—Dermatitis—Teniposide—lymphatic system cancer	0.00202	0.00225	CcSEcCtD
Penicillamine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00201	0.00224	CcSEcCtD
Penicillamine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00199	0.00222	CcSEcCtD
Penicillamine—Leukopenia—Carmustine—lymphatic system cancer	0.00198	0.00221	CcSEcCtD
Penicillamine—Anorexia—Bleomycin—lymphatic system cancer	0.00197	0.0022	CcSEcCtD
Penicillamine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00196	0.00219	CcSEcCtD
Penicillamine—Anaemia—Vincristine—lymphatic system cancer	0.00195	0.00218	CcSEcCtD
Penicillamine—Agitation—Vincristine—lymphatic system cancer	0.00194	0.00216	CcSEcCtD
Penicillamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00193	0.00215	CcSEcCtD
Penicillamine—Nausea—Teniposide—lymphatic system cancer	0.0019	0.00212	CcSEcCtD
Penicillamine—Anaemia—Mitoxantrone—lymphatic system cancer	0.0019	0.00212	CcSEcCtD
Penicillamine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00189	0.00211	CcSEcCtD
Penicillamine—Leukopenia—Vincristine—lymphatic system cancer	0.00189	0.00211	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00188	0.0021	CcSEcCtD
Penicillamine—Anxiety—Carmustine—lymphatic system cancer	0.00187	0.00209	CcSEcCtD
Penicillamine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00184	0.00205	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.0018	0.00201	CcSEcCtD
Penicillamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00179	0.002	CcSEcCtD
Penicillamine—Vomiting—Fludarabine—lymphatic system cancer	0.00179	0.002	CcSEcCtD
Penicillamine—Rash—Fludarabine—lymphatic system cancer	0.00178	0.00198	CcSEcCtD
Penicillamine—Dermatitis—Fludarabine—lymphatic system cancer	0.00177	0.00198	CcSEcCtD
Penicillamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00176	0.00197	CcSEcCtD
Penicillamine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00175	0.00195	CcSEcCtD
Penicillamine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00174	0.00194	CcSEcCtD
Penicillamine—Anorexia—Carmustine—lymphatic system cancer	0.00172	0.00192	CcSEcCtD
Penicillamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00168	0.00188	CcSEcCtD
Penicillamine—Nausea—Fludarabine—lymphatic system cancer	0.00167	0.00187	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00164	0.00183	CcSEcCtD
Penicillamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00164	0.00183	CcSEcCtD
Penicillamine—Urticaria—Bleomycin—lymphatic system cancer	0.00164	0.00183	CcSEcCtD
Penicillamine—Anorexia—Vincristine—lymphatic system cancer	0.00164	0.00183	CcSEcCtD
Penicillamine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00163	0.00182	CcSEcCtD
Penicillamine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00163	0.00182	CcSEcCtD
Penicillamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.0016	0.00178	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00157	0.00175	CcSEcCtD
Penicillamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00157	0.00175	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00153	0.00171	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00153	0.0017	CcSEcCtD
Penicillamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00152	0.0017	CcSEcCtD
Penicillamine—Decreased appetite—Vincristine—lymphatic system cancer	0.0015	0.00167	CcSEcCtD
Penicillamine—Asthma—Methotrexate—lymphatic system cancer	0.00147	0.00164	CcSEcCtD
Penicillamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00146	0.00163	CcSEcCtD
Penicillamine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00145	0.00162	CcSEcCtD
Penicillamine—Pancreatitis—Methotrexate—lymphatic system cancer	0.00144	0.00161	CcSEcCtD
Penicillamine—Body temperature increased—Carmustine—lymphatic system cancer	0.00142	0.00159	CcSEcCtD
Penicillamine—Pancytopenia—Methotrexate—lymphatic system cancer	0.00139	0.00156	CcSEcCtD
Penicillamine—Body temperature increased—Vincristine—lymphatic system cancer	0.00136	0.00152	CcSEcCtD
Penicillamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00133	0.00149	CcSEcCtD
Penicillamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00133	0.00148	CcSEcCtD
Penicillamine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00132	0.00148	CcSEcCtD
Penicillamine—Vomiting—Bleomycin—lymphatic system cancer	0.00131	0.00147	CcSEcCtD
Penicillamine—Rash—Bleomycin—lymphatic system cancer	0.0013	0.00145	CcSEcCtD
Penicillamine—Dermatitis—Bleomycin—lymphatic system cancer	0.0013	0.00145	CcSEcCtD
Penicillamine—Renal failure—Methotrexate—lymphatic system cancer	0.00129	0.00144	CcSEcCtD
Penicillamine—Stomatitis—Methotrexate—lymphatic system cancer	0.00128	0.00142	CcSEcCtD
Penicillamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00127	0.00142	CcSEcCtD
Penicillamine—Haematuria—Methotrexate—lymphatic system cancer	0.00125	0.00139	CcSEcCtD
Penicillamine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00124	0.00138	CcSEcCtD
Penicillamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00123	0.00138	CcSEcCtD
Penicillamine—Diarrhoea—Carmustine—lymphatic system cancer	0.00123	0.00138	CcSEcCtD
Penicillamine—Nausea—Bleomycin—lymphatic system cancer	0.00123	0.00137	CcSEcCtD
Penicillamine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00122	0.00136	CcSEcCtD
Penicillamine—Haemoglobin—Methotrexate—lymphatic system cancer	0.00118	0.00132	CcSEcCtD
Penicillamine—Diarrhoea—Vincristine—lymphatic system cancer	0.00118	0.00131	CcSEcCtD
Penicillamine—Haemorrhage—Methotrexate—lymphatic system cancer	0.00117	0.00131	CcSEcCtD
Penicillamine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00116	0.0013	CcSEcCtD
Penicillamine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00115	0.00129	CcSEcCtD
Penicillamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00128	CcSEcCtD
Penicillamine—Vomiting—Carmustine—lymphatic system cancer	0.00115	0.00128	CcSEcCtD
Penicillamine—Rash—Carmustine—lymphatic system cancer	0.00114	0.00127	CcSEcCtD
Penicillamine—Dermatitis—Carmustine—lymphatic system cancer	0.00114	0.00127	CcSEcCtD
Penicillamine—Tinnitus—Methotrexate—lymphatic system cancer	0.0011	0.00122	CcSEcCtD
Penicillamine—Vomiting—Vincristine—lymphatic system cancer	0.00109	0.00122	CcSEcCtD
Penicillamine—Rash—Vincristine—lymphatic system cancer	0.00108	0.00121	CcSEcCtD
Penicillamine—Dermatitis—Vincristine—lymphatic system cancer	0.00108	0.00121	CcSEcCtD
Penicillamine—Nausea—Carmustine—lymphatic system cancer	0.00107	0.0012	CcSEcCtD
Penicillamine—Angiopathy—Methotrexate—lymphatic system cancer	0.00107	0.00119	CcSEcCtD
Penicillamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00107	0.00119	CcSEcCtD
Penicillamine—Rash—Mitoxantrone—lymphatic system cancer	0.00106	0.00118	CcSEcCtD
Penicillamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00106	0.00118	CcSEcCtD
Penicillamine—Alopecia—Methotrexate—lymphatic system cancer	0.00104	0.00116	CcSEcCtD
Penicillamine—Mental disorder—Methotrexate—lymphatic system cancer	0.00103	0.00115	CcSEcCtD
Penicillamine—Nausea—Vincristine—lymphatic system cancer	0.00102	0.00114	CcSEcCtD
Penicillamine—Dysgeusia—Methotrexate—lymphatic system cancer	0.001	0.00112	CcSEcCtD
Penicillamine—Nausea—Mitoxantrone—lymphatic system cancer	0.000995	0.00111	CcSEcCtD
Penicillamine—Anaemia—Methotrexate—lymphatic system cancer	0.000945	0.00106	CcSEcCtD
Penicillamine—Leukopenia—Methotrexate—lymphatic system cancer	0.000915	0.00102	CcSEcCtD
Penicillamine—Arthralgia—Methotrexate—lymphatic system cancer	0.000871	0.000972	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000865	0.000966	CcSEcCtD
Penicillamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000817	0.000913	CcSEcCtD
Penicillamine—Skin disorder—Methotrexate—lymphatic system cancer	0.000811	0.000905	CcSEcCtD
Penicillamine—Anorexia—Methotrexate—lymphatic system cancer	0.000796	0.000888	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00076	0.000849	CcSEcCtD
Penicillamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000726	0.00081	CcSEcCtD
Penicillamine—Urticaria—Methotrexate—lymphatic system cancer	0.000663	0.00074	CcSEcCtD
Penicillamine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00066	0.000737	CcSEcCtD
Penicillamine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000615	0.000687	CcSEcCtD
Penicillamine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000571	0.000638	CcSEcCtD
Penicillamine—Vomiting—Methotrexate—lymphatic system cancer	0.000531	0.000593	CcSEcCtD
Penicillamine—Rash—Methotrexate—lymphatic system cancer	0.000526	0.000588	CcSEcCtD
Penicillamine—Dermatitis—Methotrexate—lymphatic system cancer	0.000526	0.000587	CcSEcCtD
Penicillamine—Nausea—Methotrexate—lymphatic system cancer	0.000496	0.000554	CcSEcCtD
